堃博医疗-B（02216，香港主板上市）在最新公告中称，董事会拟于2026年5月14日召开的股东周年大会上寻求股份购回一般授权。若获得股东通过，公司可在授权有效期内最多回购相当于已发行股本（不包括库存股）10%的股份，即约52,707,908股。
公告显示，上述股份购回将依据开曼群岛公司法及香港联合交易所有限公司证券上市规则进行，所需资金将来自公司在法律许可及可用财务资源范围内的自有资金。董事会认为，此举将有助于提升股东回报并优化资本结构，符合公司及全体股东的最佳利益。
根据公告内容，若授权获股东大会批准，董事会有权于联交所或其他获认可的证券交易所执行回购计划。公司同时指出，将严格遵守回购相关法律法规，确保行动的合规性与稳健性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.